STOCKHOLDERS’ EQUITY (Tables)
|
6 Months Ended |
Sep. 30, 2022 |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
SCHEDULE OF RESTRICTED STOCK AWARDS |
A
summary of the Company’s restricted stock unit awards for the period ended September 30, 2022 is as follows:
SCHEDULE OF RESTRICTED STOCK AWARDS
| |
Number Of Shares | | |
Weighted Average Grant Date Fair Value | |
| |
| | |
| |
Unvested as of April 1, 2022 | |
| 949,600 | | |
| 6.92 | |
Granted | |
| - | | |
| - | |
Vested | |
| - | | |
| - | |
Forfeited | |
| - | | |
| - | |
Unvested as of September 30, 2022 | |
| 949,600 | | |
$ | 6.92 | |
|
SCHEDULE OF FAIR VALUE OF OPTION |
The
following was utilized to calculate the fair value of options on the date of grant:
SCHEDULE OF FAIR VALUE OF OPTION
|
|
September
30,
2022 |
|
|
September
30,
2021 |
|
Risk-free
interest rate |
|
|
2.5
- 3.7 |
% |
|
|
0.1 |
% |
Expected
volatility (Beyond Air) |
|
|
87.4
- 89.1 |
% |
|
|
90.3
– 90.5 |
% |
Expected
volatility (Beyond Cancer) |
|
|
104.7
– 106.7 |
% |
|
|
n/a |
|
Dividend
yield |
|
|
0 |
% |
|
|
0 |
% |
Expected
terms (in years) |
|
|
6.25 |
|
|
|
6.25 |
|
|
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE |
The
following summarizes the components of stock-based compensation expense which include stock options and restricted stock for the three
and six months ended September 30, 2022 and September 30, 2021, respectively:
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE
(in thousands) | |
2022 | | |
2021 | | |
2022 | | |
2021 | |
| |
Three Months Ended | | |
Six Months Ended | |
| |
September 30, | | |
September 30, | |
(in thousands) | |
2022 | | |
2021 | | |
2022 | | |
2021 | |
Research and development | |
$ | 1,002 | | |
$ | 379 | | |
$ | 1,957 | | |
$ | 744 | |
General and administrative | |
| 3,713 | | |
| 776 | | |
| 7,381 | | |
| 1,627 | |
Total stock-based compensation expense | |
$ | 4,714 | | |
$ | 1,155 | | |
$ | 9,338 | | |
$ | 2,371 | |
|
SUMMARY OF COMPANY’S OUTSTANDING WARRANTS |
A
summary of the Company’s outstanding warrants as of September 30, 2022 is as follows:
SUMMARY OF COMPANY’S OUTSTANDING WARRANTS
Warrant Holders | |
Number Of Warrants | | |
Exercise Price | | |
Intrinsic Value (in thousands) | | |
Date of Expiration |
Third-party license agreement | |
| 208,333 | | |
$ | 4.80 | | |
$ | 550 | | |
January 2024 |
March 2020 loan | |
| 172,187 | | |
$ | 7.26 | | |
| 31 | | |
March 2025 |
NitricGen Agreement | |
| 80,000 | | |
$ | 6.90 | | |
| 43 | | |
January 2028 |
Total | |
| 460,520 | | |
$ | 6.08 | | |
$ | 624 | | |
|
|
2013 Beyond Air Equity Incentive Plan [Member] |
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
SCHEDULE OF OPTION ACTIVITY |
A
summary of the change in options for the six months ended September 30, 2022, is as follows:
SCHEDULE OF OPTION ACTIVITY
| |
Number Of Options | | |
Weighted Average Exercise Price Options | | |
Weighted Average Remaining Contractual Life- Options | | |
Aggregate Intrinsic Value (in thousands) | |
| |
| | |
| | |
| | |
| |
Options outstanding as of April 1, 2022 | |
| 5,508,631 | | |
$ | 5.60 | | |
| 8.1 | | |
$ | 6,831 | |
Granted | |
| 116,500 | | |
| 7.95 | | |
| - | | |
| - | |
Exercised | |
| (15,000 | ) | |
| 5.21 | | |
| - | | |
| - | |
Forfeited | |
| (28,500 | ) | |
| 5.88 | | |
| - | | |
| - | |
Outstanding as of September 30, 2022 | |
| 5,581,631 | | |
$ | 5.65 | | |
| 7.6 | | |
$ | 10,565 | |
Exercisable as of September 30, 2022 | |
| 2,548,881 | | |
$ | 4.77 | | |
| 6.3 | | |
$ | 6,879 | |
|
2021 Beyond Cancer Ltd Equity Incentive Plan [Member] |
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
SCHEDULE OF OPTION ACTIVITY |
SCHEDULE OF OPTION ACTIVITY
| |
Number Of Options | | |
Weighted Average Exercise Price–- Options | | |
Weighted Average Remaining Contractual Life- Options | | |
Aggregate Intrinsic Value (thousands) | |
| |
| | |
| | |
| | |
| |
Options outstanding as of April 1, 2022 | |
| 1,763,500 | | |
$ | 2.76 | | |
| 9.3 | | |
$ | 12,768 | |
Granted | |
| 89,000 | | |
| 10.00 | | |
| 9.6 | | |
| - | |
Exercise | |
| - | | |
| - | | |
| - | | |
| - | |
Forfeited | |
| (10,000 | ) | |
| 10,00 | | |
| 9.5 | | |
| - | |
Outstanding as of September 30, 2022 | |
| 1,842,500 | | |
$ | 3.07 | | |
| 9.3 | | |
$ | 12,759 | |
Exercisable as of September 30, 2022 | |
| - | | |
$ | - | | |
| - | | |
$ | - | |
|